SAN MATEO, Calif., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Epocrates, Inc. (Nasdaq:EPOC) today announced Peter Brandt, a member of Epocrates' board of directors, has been appointed as the company's interim president and CEO. Brandt succeeds Rose Crane who stepped down from her position as president and CEO. The board has formed a search committee and initiated a search for a permanent replacement.
"Under Rose's leadership, the company achieved an initial public offering, and she set the stage for future growth with the development and launch of innovative new products," said Patrick Jones, chairman of the Epocrates board of directors. "We thank Rose for her commitment and contributions and wish her well in her future endeavors."
Peter Brandt, who joined the company's board of directors in February 2011, has more than thirty years experience in the pharmaceutical industry. He most recently held the position of president and CEO of Noven Pharmaceuticals. He currently serves on the board of directors for Rexahn Pharmaceuticals, Auxilium Pharmaceuticals and the Population Council.
"Peter's strong leadership and extensive knowledge of the healthcare industry will benefit the company during this transition," said Jones. "We are fortunate that Peter is ready to step in and maintain positive momentum driving the company forward."
"I'm excited about this opportunity and look forward to more closely supporting the company's goals," said Brandt. "I believe in the strength of the Epocrates business and have been consistently impressed with its talented and dedicated employees. As a company, we will remain focused on delivering innovative and valuable solutions for physicians to use at the point of care. Building on our recent development milestones, strategic realignments and strong financial position, we will take advantage of the many opportunities presented for future business growth."
About Epocrates, Inc.
Epocrates, Inc. (Nasdaq:EPOC) is a leading physician platform for essential clinical content, practice tools and health industry engagement at the point of care. The Epocrates network consists of more than 1.4 million healthcare professionals, including 50 percent of U.S. physicians, who routinely use its solutions and services. Epocrates' portfolio includes top-ranked medical apps, such as the industry's #1 most used mobile drug reference, valuable manufacturer resources and a SaaS web-based electronic health record offering support. Through these intuitive and reliable resources, the company supports clinical decisions, helps improve physician workflow and impacts patient outcomes. For more information about Epocrates, please visit www.epocrates.com/company.
Epocrates is a trademark of Epocrates, Inc., in the U.S. and other countries.
The Epocrates, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10943
Forward-Looking Statements
Statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Epocrates' actual results to be materially different than those expressed in or implied by Epocrates' forward-looking statements. For Epocrates, particular uncertainties and risks include, among others: unexpected delays in Epocrates delivering new products may occur, which would cause revenues not to be as Epocrates expects; market acceptance of new products, such as its EHR, may not be as Epocrates expects, which would cause revenues not to be as Epocrates expects; and the impact of competitive products and pricing may decrease demand for Epocrates' products and/or force Epocrates to decrease the price of its products. More detailed information on these and additional factors that could affect Epocrates' actual results are described in Epocrates' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2011. Except as required by law, Epocrates undertakes no obligation to publicly update its forward-looking statements.